Seeking Alpha
18 Jul 2026, 10:10 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Assembly Biosciences has pro forma liquidity exceeding $340 million, which is expected to fund operations through 2028. — Eliminating near-term dilution risk and ensuring a multi-year runway significantly reduces financial risk for shareholders.
+0.60The company maintains a strategic antiviral platform partnership with Gilead. — Validation from a major industry player like Gilead provides credibility and potential non-dilutive funding.
+0.40ASMB's pipeline targets recurrent genital herpes, HDV, and cholestatic liver diseases with early clinical data. — While promising, early clinical data represents long-term optionality rather than immediate commercial catalysts.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company has a strengthened balance sheet, robust pipeline, and liquidity extending through 2028.
Mentioned as a robust partner in a strategic antiviral platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Proactive Investors - Finance
3h ago
